Do analysts rate ADXS or ACOG?

Alpha Cognition has a consensus target price of $14.67, indicating a potential upside of 113.18%. Given Alpha Cognition's stronger consensus rating and higher possible upside, analysts clearly believe Alpha Cognition is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Alpha Cognition 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Does the media refer more to ADXS or ACOG?

In the previous week, Alpha Cognition had 2 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 3 mentions for Alpha Cognition and 1 mentions for Ayala Pharmaceuticals. Alpha Cognition's average media sentiment score of 1.15 beat Ayala Pharmaceuticals' score of 0.00 indicating that Alpha Cognition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ayala Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alpha Cognition 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer SPRB or ADXS?

Spruce Biosciences currently has a consensus target price of $163.00, indicating a potential upside of 194.94%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Spruce Biosciences is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spruce Biosciences 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.60 Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is SPRB or ADXS more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Spruce Biosciences N/A -155.40% -101.67% Ayala Pharmaceuticals N/A N/A N/A

Does the media prefer SPRB or ADXS?

In the previous week, Spruce Biosciences had 1 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for Spruce Biosciences and 1 mentions for Ayala Pharmaceuticals. Spruce Biosciences' average media sentiment score of 0.94 beat Ayala Pharmaceuticals' score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spruce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ayala Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ENLV or ADXS more profitable?

Enlivex Therapeutics' return on equity of 248.08% beat Ayala Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Enlivex Therapeutics N/A 248.08% 206.39% Ayala Pharmaceuticals N/A N/A N/A

Does the media prefer ENLV or ADXS?

In the previous week, Enlivex Therapeutics had 1 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for Enlivex Therapeutics and 1 mentions for Ayala Pharmaceuticals. Enlivex Therapeutics' average media sentiment score of 0.93 beat Ayala Pharmaceuticals' score of 0.00 indicating that Enlivex Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enlivex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ayala Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend IFRX or ADXS?

InflaRx currently has a consensus target price of $7.00, suggesting a potential upside of 199.79%. Given InflaRx's stronger consensus rating and higher probable upside, equities analysts clearly believe InflaRx is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InflaRx 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is IFRX or ADXS more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -88.30% -65.77% Ayala Pharmaceuticals N/A N/A N/A

Does the media refer more to IFRX or ADXS?

In the previous week, InflaRx had 1 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for InflaRx and 1 mentions for Ayala Pharmaceuticals. InflaRx's average media sentiment score of 1.89 beat Ayala Pharmaceuticals' score of 0.00 indicating that InflaRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InflaRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Ayala Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ADXS or PYXS?

Pyxis Oncology has a consensus target price of $6.83, indicating a potential upside of 132.03%. Given Pyxis Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Pyxis Oncology is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Pyxis Oncology 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63

Is ADXS or PYXS more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Ayala Pharmaceuticals N/A N/A N/A Pyxis Oncology N/A -135.60% -85.00%

Does the media refer more to ADXS or PYXS?

In the previous week, Pyxis Oncology had 4 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 5 mentions for Pyxis Oncology and 1 mentions for Ayala Pharmaceuticals. Pyxis Oncology's average media sentiment score of 0.62 beat Ayala Pharmaceuticals' score of 0.00 indicating that Pyxis Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ayala Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pyxis Oncology 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ayala Pharmaceuticals (ADXS) Competitors

$0.60 0.00 (0.00%)

As of 06/29/2026

Compare

ADXS vs. ACOG, SPRB, ENLV, IFRX, and PYXS

Should you buy Ayala Pharmaceuticals stock or one of its competitors? MarketBeat compares Ayala Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ayala Pharmaceuticals include Alpha Cognition (ACOG), Spruce Biosciences (SPRB), Enlivex Therapeutics (ENLV), InflaRx (IFRX), and Pyxis Oncology (PYXS). These companies are all part of the "pharmaceutical products" industry.

How does Ayala Pharmaceuticals compare to Alpha Cognition?

Ayala Pharmaceuticals (NASDAQ:ADXS) and Alpha Cognition (NASDAQ:ACOG) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

Alpha Cognition has a consensus target price of $14.67, indicating a potential upside of 113.18%. Given Alpha Cognition's stronger consensus rating and higher possible upside, analysts clearly believe Alpha Cognition is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Alpha Cognition had 2 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 3 mentions for Alpha Cognition and 1 mentions for Ayala Pharmaceuticals. Alpha Cognition's average media sentiment score of 1.15 beat Ayala Pharmaceuticals' score of 0.00 indicating that Alpha Cognition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ayala Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alpha Cognition	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

7.2% of Ayala Pharmaceuticals shares are held by institutional investors. 0.6% of Ayala Pharmaceuticals shares are held by insiders. Comparatively, 8.6% of Alpha Cognition shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Ayala Pharmaceuticals has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market. Comparatively, Alpha Cognition has a beta of 2.36, indicating that its stock price is 136% more volatile than the broader market.

Ayala Pharmaceuticals has a net margin of 0.00% compared to Alpha Cognition's net margin of -232.23%. Ayala Pharmaceuticals' return on equity of 0.00% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
Alpha Cognition	-232.23%	-58.35%	-45.99%

Alpha Cognition has higher revenue and earnings than Ayala Pharmaceuticals. Alpha Cognition is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
Alpha Cognition	$10.83M	13.84	-$20.67M	-$1.35	N/A

Summary

Alpha Cognition beats Ayala Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to Spruce Biosciences?

Spruce Biosciences (NASDAQ:SPRB) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 4.3% of Spruce Biosciences shares are owned by company insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Spruce Biosciences had 1 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for Spruce Biosciences and 1 mentions for Ayala Pharmaceuticals. Spruce Biosciences' average media sentiment score of 0.94 beat Ayala Pharmaceuticals' score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spruce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ayala Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spruce Biosciences has higher revenue and earnings than Ayala Pharmaceuticals. Spruce Biosciences is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	30.95	-$38.97M	-$36.60	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

Spruce Biosciences has a beta of 3.12, indicating that its stock price is 212% more volatile than the broader market. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market.

Spruce Biosciences currently has a consensus target price of $163.00, indicating a potential upside of 194.94%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Spruce Biosciences is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Ayala Pharmaceuticals' return on equity of 0.00% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-155.40%	-101.67%
Ayala Pharmaceuticals	N/A	N/A	N/A

Summary

Spruce Biosciences beats Ayala Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to Enlivex Therapeutics?

Enlivex Therapeutics (NASDAQ:ENLV) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Enlivex Therapeutics presently has a consensus price target of $16.50, indicating a potential upside of 2,872.97%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Enlivex Therapeutics is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Enlivex Therapeutics had 1 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for Enlivex Therapeutics and 1 mentions for Ayala Pharmaceuticals. Enlivex Therapeutics' average media sentiment score of 0.93 beat Ayala Pharmaceuticals' score of 0.00 indicating that Enlivex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enlivex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ayala Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enlivex Therapeutics has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market.

1.0% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Enlivex Therapeutics' return on equity of 248.08% beat Ayala Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
Ayala Pharmaceuticals	N/A	N/A	N/A

Enlivex Therapeutics has higher earnings, but lower revenue than Ayala Pharmaceuticals. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$0.55	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

Summary

Enlivex Therapeutics beats Ayala Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to InflaRx?

InflaRx (NASDAQ:IFRX) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Ayala Pharmaceuticals' return on equity of 0.00% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-88.30%	-65.77%
Ayala Pharmaceuticals	N/A	N/A	N/A

InflaRx currently has a consensus target price of $7.00, suggesting a potential upside of 199.79%. Given InflaRx's stronger consensus rating and higher probable upside, equities analysts clearly believe InflaRx is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

42.4% of InflaRx shares are owned by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 16.3% of InflaRx shares are owned by insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, InflaRx had 1 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for InflaRx and 1 mentions for Ayala Pharmaceuticals. InflaRx's average media sentiment score of 1.89 beat Ayala Pharmaceuticals' score of 0.00 indicating that InflaRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InflaRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Ayala Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

InflaRx has a beta of 2.42, suggesting that its stock price is 142% more volatile than the broader market. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market.

Ayala Pharmaceuticals has higher revenue and earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	5,626.57	-$51.63M	-$0.71	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

Summary

InflaRx beats Ayala Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to Pyxis Oncology?

Ayala Pharmaceuticals (NASDAQ:ADXS) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

In the previous week, Pyxis Oncology had 4 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 5 mentions for Pyxis Oncology and 1 mentions for Ayala Pharmaceuticals. Pyxis Oncology's average media sentiment score of 0.62 beat Ayala Pharmaceuticals' score of 0.00 indicating that Pyxis Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ayala Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pyxis Oncology	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pyxis Oncology has a consensus target price of $6.83, indicating a potential upside of 132.03%. Given Pyxis Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Pyxis Oncology is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Ayala Pharmaceuticals has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market.

7.2% of Ayala Pharmaceuticals shares are held by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are held by institutional investors. 0.6% of Ayala Pharmaceuticals shares are held by insiders. Comparatively, 5.7% of Pyxis Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Ayala Pharmaceuticals' return on equity of 0.00% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
Pyxis Oncology	N/A	-135.60%	-85.00%

Ayala Pharmaceuticals has higher earnings, but lower revenue than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
Pyxis Oncology	$13.86M	13.46	-$79.62M	-$1.31	N/A

Summary

Pyxis Oncology beats Ayala Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get Ayala Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADXS vs. The Competition

Export

Metric	Ayala Pharmaceuticals	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$35.79M	$1.01B	$6.79B	$12.60B
Dividend Yield	N/A	4.84%	2.66%	6.21%
P/E Ratio	-0.08	1.50	25.78	24.83
Price / Sales	11.05	114.57	562.11	117.09
Price / Cash	N/A	20.06	29.14	36.96
Price / Book	-0.29	8.09	11.09	6.56
Net Income	-$48.07M	-$3.83M	$3.57B	$336.85M
7 Day Performance	N/A	2.38%	2.54%	3.19%
1 Month Performance	N/A	1.88%	0.89%	1.62%
1 Year Performance	N/A	50.28%	36.92%	31.65%

Ayala Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADXS Ayala Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$35.79M	$3.24M	N/A	20	News Coverage
ACOG Alpha Cognition	4.014 of 5 stars	$6.55 -0.5%	$14.67 +123.9%	-25.2%	$142.57M	$10.22M	N/A	N/A	News Coverage Positive News
SPRB Spruce Biosciences	2.8648 of 5 stars	$52.18 +0.6%	$163.00 +212.4%	+934.8%	$142.44M	$4.91M	N/A	20	News Coverage
ENLV Enlivex Therapeutics	3.379 of 5 stars	$0.59 -1.8%	$16.50 +2,677.8%	-51.7%	$140.77M	N/A	N/A	70
IFRX InflaRx	2.7785 of 5 stars	$1.93 -0.3%	$7.00 +263.6%	+182.2%	$139.16M	$30K	N/A	60	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADXS) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ayala Pharmaceuticals (ADXS) Competitors

ADXS vs. ACOG, SPRB, ENLV, IFRX, and PYXS

How does Ayala Pharmaceuticals compare to Alpha Cognition?

Summary

How does Ayala Pharmaceuticals compare to Spruce Biosciences?

Summary

How does Ayala Pharmaceuticals compare to Enlivex Therapeutics?

Summary

How does Ayala Pharmaceuticals compare to InflaRx?

Summary

How does Ayala Pharmaceuticals compare to Pyxis Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXS vs. The Competition

Ayala Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ayala Pharmaceuticals (ADXS) Competitors

ADXS vs. ACOG, SPRB, ENLV, IFRX, and PYXS

How does Ayala Pharmaceuticals compare to Alpha Cognition?

Do analysts rate ADXS or ACOG?

Does the media refer more to ADXS or ACOG?

Do insiders and institutionals have more ownership in ADXS or ACOG?

Which has more volatility & risk, ADXS or ACOG?

Is ADXS or ACOG more profitable?

Which has stronger valuation & earnings, ADXS or ACOG?

Summary

How does Ayala Pharmaceuticals compare to Spruce Biosciences?

Do institutionals and insiders have more ownership in SPRB or ADXS?

Does the media prefer SPRB or ADXS?

Which has preferable earnings and valuation, SPRB or ADXS?

Which has more risk and volatility, SPRB or ADXS?

Do analysts prefer SPRB or ADXS?

Is SPRB or ADXS more profitable?

Summary

How does Ayala Pharmaceuticals compare to Enlivex Therapeutics?

Do analysts prefer ENLV or ADXS?

Does the media prefer ENLV or ADXS?

Which has more volatility and risk, ENLV or ADXS?

Do insiders and institutionals have more ownership in ENLV or ADXS?

Is ENLV or ADXS more profitable?

Which has stronger valuation and earnings, ENLV or ADXS?

Summary

How does Ayala Pharmaceuticals compare to InflaRx?

Is IFRX or ADXS more profitable?

Do analysts recommend IFRX or ADXS?

Do institutionals & insiders hold more shares of IFRX or ADXS?

Does the media refer more to IFRX or ADXS?

Which has more risk and volatility, IFRX or ADXS?

Which has stronger valuation and earnings, IFRX or ADXS?

Summary

How does Ayala Pharmaceuticals compare to Pyxis Oncology?

Does the media refer more to ADXS or PYXS?

Do analysts prefer ADXS or PYXS?

Which has more risk and volatility, ADXS or PYXS?

Do insiders and institutionals believe in ADXS or PYXS?

Is ADXS or PYXS more profitable?

Which has stronger earnings & valuation, ADXS or PYXS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXS vs. The Competition

Ayala Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools